NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Korsana Biosciences

Korsana Biosciences

Private
Waltham, MassachusettsHealthcare & Life Scienceshttps://korsana.com/

Last Round

PIPE

Apr 1, 2026

Total Funding Raised

$425M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Korsana Biosciences is a biotechnology company developing brain-penetrant therapeutics for neurodegenerative diseases using its proprietary blood-brain barrier shuttle platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologyAlzheimer's diseaseblood-brain barrierBBB shuttleneurodegenerative diseaseantibody therapydrug deliveryCNS therapeuticscentral nervous systemsubcutaneous administrationdrug discoverybiologicsneurotechbrain drug deliverypre-clinical biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Korsana Biosciences Comps

Public and private peers based on sector, stage, and business model.

Korsana Biosciences comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Korsana Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
PIPEApr 1, 2026
SeedFeb 18, 2026
Series ASep 1, 2025
SeedDec 1, 2024

Key People

Founding team and executive leadership

Jonathan Violin

President & CEO

Executive Team

Mark Vignola

Chief Financial Officer

Executive Team

Korsana Biosciences Investors

Notable investors and investment history

Korsana Biosciences investors
InvestorRounds
Janus Henderson GroupPIPE, Seed, Series A
RA Capital ManagementPIPE
TCG CrossoverPIPE, Seed, Series A
ForbionPIPE
Fairmount Funds ManagementSeed, PIPE
Commodore CapitalPIPE
Kalehua Capital ManagementPIPE

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 27, 2026

    Grew 53% QoQ from 17 to 26 employees.

  • Apr 1, 2026

    $380M round led by Venrock and Fairmount Funds Management.

Korsana Biosciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Korsana Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Korsana Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersWaltham, Massachusetts
Employee Range26
Year Founded2024
Last FundingApr 1, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.